Search: WFRF:(Jurgute R. R.)
> (2021) >
Direct and Indirect...
Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
2021-07-22
-
Springer Science and Business Media LLC,2021
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/306940
-
https://gup.ub.gu.se/publication/306940URI
-
https://doi.org/10.1007/s40261-021-01057-yDOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background and Objective Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-season, randomised controlled trial investigated the effectiveness of oseltamivir for treating ILI in 15 European countries. We aimed to evaluate whether patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone. Methods Resource use data were extracted from participants' daily diaries. Itemised country-specific unit costs were collected through official tariffs, pharmacies or literature. Costs were converted to 2018 values. The null hypothesis was tested based on one-sided credible intervals (CrIs) obtained by bootstrapping. Base-case analysis estimated direct cost and productivity losses using itemised costed resource use and the human capital approach. Scenario analyses with self-reported spending rather than itemised costing were also performed. Results Patients receiving oseltamivir (N = 1306) reported fewer healthcare visits, medication uses, hospital attendances and paid-work hours lost than the other patients (N = 1298). Excluding the oseltamivir cost, the average direct costs were lower in patients treated with oseltamivir from all perspectives, but these differences were not statistically significant (perspective of patient: euro17 [0-95% Crl: 16-19] vs. euro24 [5-100% Crl: 18-29]; healthcare provider: euro37 [28-67] vs. euro44 [25-55]; healthcare payers: euro54 [45-85] vs. euro68 [45-81]; and society: euro423 [399-478] vs. euro451 [390-478]). Scenario and age-group analyses confirmed these findings, but with some between-country differences. Conclusion The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Bilcke, J.
(author)
-
van der Velden, A. W.
(author)
-
Bongard, E.
(author)
-
Bruyndonckx, R.
(author)
-
Sundvall, Pär-DanielGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine(Swepub:gu)xsupar
(author)
-
Harbin, N. J.
(author)
-
Coenen, S.
(author)
-
Francis, N.
(author)
-
Bruno, P.
(author)
-
Garcia-Sangenis, A.
(author)
-
Glinz, D.
(author)
-
Kosiek, K.
(author)
-
Miko-Pauer, R.
(author)
-
Jurgute, R. R.
(author)
-
Seifert, B.
(author)
-
Tsakountakis, N.
(author)
-
Aabenhus, R.
(author)
-
Butler, C. C.
(author)
-
Beutels, P.
(author)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för samhällsmedicin och folkhälsa
(creator_code:org_t)
Related titles
-
In:Clinical Drug Investigation: Springer Science and Business Media LLC41:8, s. 685-6991173-25631179-1918
Internet link
Find in a library
To the university's database
- By the author/editor
-
Li, X.
-
Bilcke, J.
-
van der Velden, ...
-
Bongard, E.
-
Bruyndonckx, R.
-
Sundvall, Pär-Da ...
-
show more...
-
Harbin, N. J.
-
Coenen, S.
-
Francis, N.
-
Bruno, P.
-
Garcia-Sangenis, ...
-
Glinz, D.
-
Kosiek, K.
-
Miko-Pauer, R.
-
Jurgute, R. R.
-
Seifert, B.
-
Tsakountakis, N.
-
Aabenhus, R.
-
Butler, C. C.
-
Beutels, P.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Infectious Medic ...
- Articles in the publication
-
Clinical Drug In ...
- By the university
-
University of Gothenburg